Merck falsified its mumps vaccine efficacy results, say former employees.
Merck knowingly falsified its mumps vaccine test results to fabricate a “95% efficacy rate” say former Merck virologists Stephen Krahling and Joan Wlochowski in their shocking False Claims Act document. Read more…
Read more: Go to page 5 onward. ““We identified a statistically significant increased risk of noninfluenza respiratory virus infection amongTIV recipients (Table 3), including significant increases in the risk of rhinovirus and coxsackie/echovirus infection. Being protected against influenza, TIV (vaccine) recipients may lack temporary non-specific immunity that protected against other respiratory viruses.
VLA comment:
Dr. Paul G. King also hotlinks the two studies in his footnotes. This is particularly strategically critical to the healthcare workers dilemma. If a healthcare worker is forced to get the flu shot, he/she is more (emphasis added) vulnerable to the pneumonia virus, for example and other virus that may then infect the patients.
Excerpts:
-In 1979, Sweden abandoned the whooping cough vaccine due to its ineffectiveness. Out of 5,140 cases in 1978, it was found that 84% had been vaccinated three times! (BMJ 283:696-697, 1981)
-In the UK between 1970 and 1990, over 200,000 cases of whooping cough occurred in fully vaccinated children. (Community Disease Surveillance Centre, UK)
– In the 1970s, a tuberculosis vaccine trial in India involving 260,000 people revealed that more cases of TB occurred in the vaccinated than the unvaccinated. (The Lancet 12/1/80 p73) Read more…
FDA Approves Investigational Trials Assessing Cannabidiol For Pediatric Epilepsy
Washington, DC: The US Food and Drug Administration has approved two clinical trials to assess the efficacy of cannabidiol (CBD), a nonpsychoactive plant cannabinoid, in the treatment of intractable pediatric epilepsy. The two approved trials will take place at New York Medical School and at the University of California at San Francisco, according to an online report in the journal O’Shaughnessy’s. The cannabidiol formulations in the trials will be provided by British biotechnology firmGW Pharmaceuticals, which produces organic cannabinoid extract medicines, including Sativex. Will doctors throughout the U.S. be called on to submit INDs on behalf of pediatric epilepsy patients whose families want access to Epidiolex™? Interested doctors should direct inquiries to GW’s Associate Medical Director at medicaldirector@gwpharm.com.
Cannabidiol has been documented to possess a variety of therapeutic properties in preclinical models, including anti-epileptic activity. Clinical trials have shown the oral administration of CBD to be “safe and well tolerated” in healthy subjects.
In recent months, several national broadcasts have highlighted the use of CBD-rich oils to treat seizures associated with a pediatric form of intractable epilepsy known as Dravet Syndrome. Read more…
AN OPEN LETTER by Dr. Paul G. King
There are few professionals who have the profile and international reputation of our founding team, which includes people who have risked their careers in speaking out about adverse drug events, such as David Healy and Nancy Olivieri, as well as international experts on pharmaco-vigilance such as Ralph Edwards from World Health Organization’s Uppsala Monitoring Center.
115 children were randomized to trivalent inactivated influenza vaccine (TIV) or placebo. Over the following 9 months, TIV recipients had an increased risk of virologically confirmed non-influenza infections (relative risk: 4.40; 95% confidence interval: 1.31-14.8). Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses.”